Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
Top Cited Papers
Open Access
- 1 July 2015
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 1 (4), 448-455
- https://doi.org/10.1001/jamaoncol.2015.0830
Abstract
The presence of tumor-infiltrating lymphocytes (TILs) has been shown to have significant positive prognostic relevance for certain subtypes of breast cancer.1-5 Tumor-infiltrating lymphocytes have also been reported to be associated with improved distant metastases–free survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, as well as increased rates of pathological complete response (pCR) with neoadjuvant trastuzumab and chemotherapy.1-3 Increasingly, oncogenic addiction, in which tumors become dependent on a sole oncogenic pathway for growth, is thought to also promote a tumor microenvironment conducive to immune escape.6,7 Although this has not been shown yet for HER2 oncogenic signaling, one could speculate that anti-HER2 therapy may not only work in a cell-intrinsic manner but may also reverse HER2-induced immunosuppression as a mechanism of action.Keywords
This publication has 20 references indexed in Scilit:
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnnals Of Oncology, 2014
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- The immune system and response to HER2-targeted treatment in breast cancerThe Lancet Oncology, 2014
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsCancer Discovery, 2013
- An International Ki67 Reproducibility StudyJNCI Journal of the National Cancer Institute, 2013
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2012
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationCancer Cell, 2010
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- REporting recommendations for tumor MARKer prognostic studies (REMARK)Breast Cancer Research and Treatment, 2006